{"nctId":"NCT02250807","briefTitle":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection","startDateStruct":{"date":"2015-01"},"conditions":["Chronic Hepatitis C","Genotype 4 Chronic Hepatitis C"],"count":40,"armGroups":[{"label":"Simeprevir and Sofosbuvir","type":"EXPERIMENTAL","interventionNames":["Drug: Simeprevir","Drug: Sofosbuvir"]}],"interventions":[{"name":"Simeprevir","otherNames":["TMC435"]},{"name":"Sofosbuvir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with confirmed hepatitis C virus (HCV) with HCV RNA greater than (\\>) 10000 international unit per milliliter (IU/mL)\n* Subjects who are treatment naive or treatment-experienced.\n* Subjects must have documentation of a liver biopsy or fibroscan or agree to have one during screening\n* Subjects with cirrhosis must have an hepatic imaging procedure (ultrasound, CT scan or magnetic resonance imaging \\[MRI\\]) within 6 months before the screening visit (or during the screening period) with no findings suspicious for hepatocellular carcinoma (HCC)\n* Women of childbearing potential or men with a female partner of childbearing potential must agree to use an effective form of contraception, or not be heterosexually active, or of nonchildbearing potential\n\nExclusion Criteria:\n\n* Evidence of clinical hepatic decompensation\n* Any liver disease of non-HCV etiology\n* Subjects with a past history of treatment with an approved or investigational DAA\n* Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening)\n* Infection/co-infection with HCV non-genotype 4","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Treatment (EOT) (SVR12)","description":"SVR12 is defined as the percentage of participants with hepatitis C virus ribonucleic acid (HCV RNA) less than (\\<) lower limit of quantification (LLOQ; 15 international unit per milliliter \\[IU/mL\\]) detectable or undetectable 12 weeks after actual EOT.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 4 Weeks After End of Therapy (SVR4)","description":"SVR4 is defined as the percentage of participants with hepatitis C virus ribonucleic acid (HCV RNA) less than (\\<) lower limit of quantification (LLOQ; 15 international unit per milliliter \\[IU/mL\\]) detectable or undetectable 4 weeks after actual EOT.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 24 Weeks After End of Therapy (SVR24)","description":"Participants were considered to have reached SVR24, if at the time point of SVR24 (that is \\[i.e.\\], 24 weeks after the end of treatment \\[EOT\\]) the following condition has been met: HCV RNA \\< lower limit of quantification (LLOQ), i.e., 15 IU/mL, detectable or undetectable.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Response of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)","description":"Percentage of participants with HCV RNA less than (\\<) 15 IU/mL undetectable or detectable or detectable /undetectable at specific time points were observed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-Treatment Failure","description":"Participants were considered on-treatment failures if they have at EOT (confirmed) detectable HCV RNA, i.e., \\<LLOQ detectable or \\>=LLOQ.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Breakthrough","description":"Participants with confirmed \\>1.0 log10 increase in HCV RNA from nadir or confirmed HCV RNA \\>100 IU/mL in participants who had previously achieved HCV RNA \\<LLOQ.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Relapse","description":"Participants were considered to have viral relapse if they did not achieve SVR12 and meet the following conditions: 1) at EOT, HCV RNA less than (\\<)LLOQ, undetectable, and 2) during the follow-up period, HCV RNA greater than or equal to (\\>=)LLOQ.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["Headache","Asthenia","Catarrh","Erythema","Rash"]}}}